Lilly(US:LLY) 智通财经网·2025-10-15 12:32Core Insights - Eli Lilly's oral weight loss candidate orforglipron has achieved primary endpoints in two Phase 3 clinical trials for type 2 diabetes, indicating its potential in blood sugar control [1][2] Group 1: Clinical Trial Results - The ACHIEVE-2 trial showed that orforglipron reduced the A1C levels by 1.7%, compared to a 0.8% reduction with AstraZeneca's Farxiga [1] - The ACHIEVE-5 trial demonstrated an additional A1C reduction of 2.1% when orforglipron was used in conjunction with glargine insulin [1] - Both trials tested three doses of orforglipron: 3mg, 12mg, and 36mg over a 40-week period [1] Group 2: Future Plans and Approvals - Eli Lilly plans to seek global regulatory approval for orforglipron for type 2 diabetes in the first quarter of 2026 [2] - The company aims to submit approval data for orforglipron's use in obesity treatment by the end of 2025 [2] - Safety and tolerability data were consistent with previous trials, and treatment interruption rates were similar [2]